Baird Medical Investment Holdings Ltd

Baird Medical Investment Holdings Limited operates as a specialized healthcare innovator focused exclusively on thyroid-related diseases, aiming to transform traditional thyroid treatment through intelligent, non-invasive solutions. The company's mission is to build an ecosystem spanning early screening, diagnosis, robotic-assisted ablation, and post-treatment care. Its core strengths include the successful development and commercialization of the thyroid microwave ablation system and an active R&D pipeline featuring AI-integrated robotic systems. Baird Medical ranked first among microwave ablation medical device providers in the treatment of thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of microwave ablation needles in 2022, and was the third largest microwave ablation medical device provider in the PRC by sales revenue in the same year ¹.

The company's core business model primarily involves the design, development, manufacturing, and sale of its proprietary microwave ablation (MWA) medical devices. In 2025, 2024, and 2023, sales of MWA medical devices represented 100.0%, 100.0%, and 98.4% of total revenue, respectively ². The remaining revenue in 2023, 1.6%, came from sales of other medical devices ². The company's products are ultimately sold to hospitals through direct sales, deliverers, or distributors. As of December 31, 2025, the company had a network of approximately 614 hospitals in China purchasing its products, including approximately 329 Grade III hospitals ³.

The product portfolio available for sale includes microwave ablation apparatus approved for the treatment of liver cancer and thyroid nodule, long microwave ablation needles, and fine microwave ablation needles. As of the date of the annual report, the company has sold approximately 100,000 single-use microwave ablation needles ⁴ and over 1,300 units of microwave ablation therapeutic apparatus ⁵. The company also develops the system and monitoring software embedded in its proprietary microwave ablation therapeutic apparatus, holding 28 registered software copyrights as of December 31, 2025 ⁶. In 2025, MWA needles generated $17,214,751 in revenue, representing 76% of total revenue, while MWA therapeutic apparatus generated $5,322,265, accounting for 24% of total revenue ⁷.

For the fiscal year ended December 31, 2025, Baird Medical reported total revenues of $22,537,016 ⁸, a decrease of 39.2% from $37,037,108 in 2024 ⁹. Cost of revenues decreased by 16.7% from $4,383,363 in 2024 to $3,653,278 in 2025 ¹⁰. Gross profit was $18,883,738 ¹¹, resulting in a gross profit margin of 83.8% ¹². Operating expenses totaled $44,514,543 ¹³, leading to a loss from operations of $25,630,805 ¹⁴. The company reported a net loss of $27,541,124 ¹⁵, with diluted EPS of $(0.98) ¹⁶. Cash and cash equivalents were not explicitly stated as a single figure in the provided text. Total bank loans, which represent financial liabilities, were $10,100,000 as of December 31, 2025 ¹⁷.

Comparing 2025 to 2024, total revenues decreased by 39.2% from $37.0 million to $22.5 million ⁹. This was primarily driven by a decrease in demand and sales of MWA devices, with revenue from direct customers falling from $19.8 million in 2024 to $4.1 million in 2025 ¹⁸. Conversely, revenue from distributors increased from $17.2 million in 2024 to $18.4 million in 2025, mainly due to an increase in selling price ¹⁹. Gross profit margin decreased from 88.2% in 2024 to 83.8% in 2025 ¹². Operating expenses significantly increased, with selling and marketing expenses rising from $4,061,116 in 2024 to $10,264,507 in 2025 ²⁰, and research and development expenses increasing from $6,174,365 in 2024 to $20,131,012 in 2025 ²¹. General and administrative expenses also increased from $7,103,226 in 2024 to $14,119,024 in 2025 ²². These increases in operating expenses, coupled with the revenue decline, resulted in a shift from an operating income of $15,315,038 in 2024 to an operating loss of $25,630,805 in 2025 ¹⁴.

During the reported period, Baird Medical continued its focus on R&D, with expenses increasing to $20.1 million in 2025, primarily due to increased FDA certification fees, CE Marking fees, and R&D expenditures on AI ablation systems and equipment ²¹. The company also successfully obtained the registration certificate for the Class III Certificate for MWA needles and one registration certificate for Class II medical devices in the PRC related to disposable sterile biopsy needles ²³. In terms of corporate structure, the company completed the filing procedures in connection with the Business Combination under the Overseas Listing Trial Measures on January 2, 2024 ²⁴.

Baird Medical's future profitability may be negatively affected by low-margin sales and competition strategies adopted by competitors, increasing costs of raw materials, and increasing selling and distribution costs due to the expansion of its sales and distribution network, which may render its high gross profit margin unsustainable ²⁵. The company also faces the risk that its products may be covered by centralized national procurement in the future, which could lead to a decrease in product prices and harm profitability if sales volume increases do not fully compensate for such price reductions ²⁶.

A major growth area for Baird Medical is the expansion of its product indications and the development of new medical devices. The company has five types of pipeline products that require product registration testing and clinical trials to obtain Class III medical device registration certificates ²⁷. Specifically, Baird Medical has engaged Nanjing Huitong Medical Technology Co., Ltd. to assist with applications for Class III medical device registration certificates for existing Class II microwave ablation needles for liver cancer and thyroid nodules, and to expand indications on its Class III medical device registration certificate to include breast lumps, pulmonary nodules, varicose veins, bone tumors, and uterine fibroids, with all such indications expected to be obtained by 2026 ²⁸. The company intends to focus its efforts on the research and development, manufacturing, and sales of microwave ablation products, and will focus on the development of AI surgical machines and other minimally invasive medical devices for surgical procedures ²⁹.

The company's operational outlook includes continued investment in research and development, with R&D expenses increasing to $20.1 million in 2025, driven by FDA certification fees, CE Marking fees, and expenditures on AI ablation systems and equipment ²¹. This indicates a strategic focus on enhancing its product portfolio and expanding into new technologies. The company also plans to recruit additional qualified accounting and financial reporting personnel with expertise in U.S. GAAP and SEC requirements and continues to enhance its accounting policies and procedures documentation to establish a comprehensive manual in accordance with U.S. GAAP to remediate identified material weaknesses in internal control over financial reporting ³⁰.

Baird Medical's planned capital allocation includes significant R&D spending, which increased by $13.9 million from $6.2 million in 2024 to $20.1 million in 2025 ²¹. The company does not intend to pay any cash dividends before it becomes profitable, which may not occur in the foreseeable future ³¹. The 2024 Equity Incentive Plan has an evergreen feature, with the share reserve automatically increasing by 1,229,381 Ordinary Shares effective January 1, 2026 ³².

The company faces structural headwinds and execution risks, including potential delays or failures in product registration testing or clinical trials for its pipeline products, which could prevent timely regulatory approvals and commercialization ²⁷. The unpredictability, length, and cost of the filing and registration process, including potential requirements for clinical trials or monitoring, pose significant risks ³³. Furthermore, the company's reliance on a concentrated customer base, with two largest customers accounting for 23.3% and 12.0% of total revenue in 2025, presents a risk if these relationships are not maintained ³⁴.

Geographic, regulatory, and macro factors identified as constraints include the evolving regulatory framework in China, particularly regarding medical devices, which could lead to increased compliance costs or prevent successful development and commercialization of products ³⁵. The potential for centralized national procurement to cover the company's products could lead to price decreases and impact profitability ²⁶. Additionally, the company is subject to uncertainties in the interpretation and enforcement of PRC laws, rules, and regulations, which could materially adversely affect its business ³⁶. The company's operations are primarily in China, making it susceptible to changes in PRC economic, political, and social conditions or government policies ³⁷.

Baird Medical faces several material risks, including those related to its limited operating history and the potential unsustainability of its high gross profit margin ²⁵. The company may be unable to obtain, maintain, or renew necessary regulatory filings and registration certificates for its microwave medical devices in a timely manner, or at all, which could force suspension of sales or cancellation of certificates ³³. Customer concentration is a significant risk, with two largest customers accounting for 23.3% and 12.0% of total revenue in 2025 ³⁴. The company is also exposed to the risk of unsuccessful product registration testing or clinical trials for its five types of pipeline products ²⁷. Supply chain disruptions and increases in raw material costs, particularly given reliance on a few major suppliers (the largest supplier in 2025 accounted for 46.0% of total cost of revenues ³⁸), could impair manufacturing and profitability. Information technology systems are vulnerable to security breaches and cyber-attacks, which could lead to data loss, operational disruptions, and regulatory sanctions ³⁹. The company has identified material weaknesses in internal control over financial reporting, including a lack of sufficient financial reporting and accounting personnel with U.S. GAAP and SEC reporting knowledge, and inadequate accounting policies and procedures ³⁰. Furthermore, the company may be required to repurchase previously issued convertible redeemable preference shares, with an outstanding repurchase request for 174,825 Preference Shares valued at RMB17.8 million as of September 30, 2023 ⁴⁰. Geopolitical risks include potential changes in United States and international trade policies towards China, with the U.S. having imposed tariffs of up to 245% on Chinese imports in April 2025, and China retaliating with tariffs of up to 125% on U.S. goods ⁴¹. The company's securities also face delisting risk under the HFCAA if the PCAOB is unable to inspect its auditors for two consecutive years ⁴².

Management's message to shareholders emphasizes the company's position as a specialized healthcare innovator dedicated to thyroid-related diseases, aiming to transform traditional treatments through intelligent, non-invasive solutions. They highlight the mission to build an ecosystem spanning early screening, diagnosis, robotic-assisted ablation, and post-treatment care, leveraging core strengths in the successful development and commercialization of the thyroid microwave ablation system and an active R&D pipeline featuring AI-integrated robotic systems. Management stresses the company's category focus, full-stack technology strategy, and proven regulatory and commercial execution as unique differentiators, positioning them to become the first global platform company dedicated to precision thyroid health. A key strategic priority is the continued investment in research and development, as evidenced by the significant increase in R&D expenses to $20.1 million in 2025, driven by FDA certification fees, CE Marking fees, and expenditures on AI ablation systems and equipment ²¹. Another priority is the expansion of product indications, with applications for Class III medical device registration certificates for existing Class II microwave ablation needles for liver cancer and thyroid nodules, and to expand indications to include breast lumps, pulmonary nodules, varicose veins, bone tumors, and uterine fibroids, all expected by 2026 ²⁸. Finally, management is focused on strengthening internal controls and financial reporting, actively monitoring the remediation plan for identified material weaknesses, including recruiting qualified accounting and financial reporting personnel and enhancing accounting policies and procedures documentation ³⁰.